stockrow
Saturday 7 November 2026
Export GYRE’s income statement to Excel — free account
Gyre Therapeutics, Inc.
GYRE Healthcare Biotechnology
- Revenue
- +7.75%
- EPS
- −200.0%
- Free cash flow
- −129.9%
Quarter to September 2026, against a year earlier
4.72
0.71
+17.71%
Follow GYRE
Alert me
Gyre Therapeutics, Inc. (GYRE) P/E ratio
Gyre Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 184× (August 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 128× | 48.52% |
| FY2024 | 86.4× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 128× | 29.05% |
| 34 more quarters | Free account |
Against its own ten years
Low 0.0×
High 184×
Ten-year median
0.0×
Current reading's percentile
79
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GYRE Gyre Therapeutics, Inc. | n/m |
| PHAT Phathom Pharmaceuticals, Inc. compare | n/m |
| OCS Oculis Holding AG compare | n/m |
| PRTA Prothena Corporation plc compare | n/m |
| PRTCY PureTech Health PLC Sponsored ADR compare | n/m |
| EPRX Eupraxia Pharmaceuticals Inc. compare | n/m |
| ARVN Arvinas, Inc. compare | n/m |
| ASMB Assembly Biosciences, Inc. compare | n/m |
| CRMD CorMedix Inc compare | 2.2× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)